Tempus AI (NASDAQ: TEM) has announced an expanded, multi-year collaboration with Merck & Co. Inc. (NYSE: MRK) to accelerate AI-driven precision medicine, focusing on discovering and developing precision medicine biomarkers. This partnership will leverage Tempus’s data and Lens Platform to support Merck’s oncology and broader therapeutic portfolios. Despite the positive news, Tempus AI shares were down due to a broader market downturn.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
AI-Powered Tempus Inks New Multi-Year Merck Deal
Tempus AI (NASDAQ: TEM) has announced an expanded, multi-year collaboration with Merck & Co. Inc. (NYSE: MRK) to accelerate AI-driven precision medicine, focusing on discovering and developing precision medicine biomarkers. This partnership will leverage Tempus’s data and Lens Platform to support Merck’s oncology and broader therapeutic portfolios. Despite the positive news, Tempus AI shares were down due to a broader market downturn.